INTERIM REPORT JANUARY–DECEMBER 2010

The January – December period and fourth quarter 2010 in brief· Net sales amounted to MSEK 0.0 (5.9), with MSEK 0.0 (0.0) in the fourth quarter · Net loss was MSEK 163.5 (154.6), with MSEK 50.1 (37.6) in the fourth quarter · Loss per share was SEK 0.67 (0.78), with SEK 0.20 (0.19) in the fourth quarter · Cash flow from operating activities was MSEK -158,9 (-146.9), with MSEK -44.3 (-30.1) in the fourth quarter · Cash and cash equivalents and other short-term investments totaled MSEK 395.0 (237.2) at the end of the period · On March 11, 2010, clinical phase II results on